Compare Ecolab Inc. (ECL) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Natera Inc. Common Stock — how do they compare? Ecolab Inc. trades at $287.68 (market cap $80.08B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Ecolab Inc. is the larger of the two by market cap, and Ecolab Inc. pays a 1.02% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 91 Days and Natera Inc. Common Stock for 0 Days on average.
| ECL | NTRA | |
|---|---|---|
Market Cap | $80.08B | $57.03B |
Volume | 1,150,296 | 1,131,157 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $425.64 |
52-Week Low | $245.73 | $179.42 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $88.86B | $56.18B |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $287.79, up 1.23% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals, including a 12.57% net income margin and 21.85% ROE, with revenue growth from $16.08B in 2025 to a projected $16.8B in 2026. Recent news highlights its dividend consistency and High-Tech segment growth, while institutional buying and insider purchases reflect confidence.
Outlook is positive with a consensus price target of $326.38, implying 13% upside, driven by earnings beats and digital expansion. Risks include elevated P/E of 38.34 and rising debt from the CoolIT acquisition. The stock remains a buy for growth-oriented investors, balancing steady cash flows with execution risks in a competitive market.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
